×
About 4,563 results

ALLMedicine™ Cutaneous Melanoma Center

Research & Reviews  1,671 results

Squaring the circle: circRNAs in melanoma.
https://doi.org/10.1038/s41388-021-01977-1 10.1038/nature12477 10.1038/nature22071 10.1016/j.ccell.2018.06.005 10.1056/NEJMoa1502583 10.1016/j.cell.2015.05.044 10.1038/ng1054 10.1007/s10585-018-9893-y 10.1038/s41467-021-21576-8 10.1101/gad.329771.119 10.1080/15592294.2014.1003746 10.1142/S2591722620400104 10.1038/nature17161 10.1038/s41594-018-0143-4 10.3390/cancers13061408 10.1038/s41580-020-0243-y 10.1016/j.tcb.2019.12.004 10.1080/15476286.2015.1020271 10.1016/j.molcel.2014.08.019 10.1016/j.cell.2015.02.014 10.1038/ncomms14741 10.1016/j.celrep.2014.12.019 10.1172/JCI62980 10.1016/j.molcel.2017.10.034 10.1186/s13059-014-0409-z 10.1261/rna.035667.112 10.1038/nature11928 10.1016/j.molcel.2015.03.027 10.1371/journal.pone.0030733 10.1371/journal.pgen.1003777 10.1186/s13059-015-0690-5 10.1186/s13059-015-0801-3 10.1016/j.celrep.2014.10.062 10.1038/nn.3975 10.1038/nature11993 10.1016/0092-8674(93)90279-Y 10.1016/j.cell.2011.07.014 10.1158/2159-8290.CD-13-0202 10.1038/cdd.2016.133 10.1093/nar/gkw027 10.1038/ncomms12429 10.1080/15476286.2017.1279788 10.1038/cdd.2017.86 10.1016/j.ymthe.2017.05.022 10.1038/nsmb.2959 10.1016/j.molcel.2013.08.017 10.1038/nplants.2017.53 10.1261/rna.048272.114 10.1016/j.molcel.2017.02.021 10.1038/cr.2017.31 10.1038/s41388-018-0230-3 10.1038/s41388-017-0019-9 10.1186/s13059-019-1685-4 10.1093/jnci/djx166 10.1186/s12943-019-1010-6 10.1038/s41467-018-06862-2 10.1016/j.molcel.2017.02.017 10.1093/nar/gkaa704 10.1038/emboj.2011.359 10.1371/journal.pgen.1007114 10.1016/j.ccell.2019.12.007 10.1038/s41467-020-18355-2 10.1016/j.isci.2020.101345 10.1126/science.aam8526 10.18632/oncotarget.9421 10.1016/j.bbrc.2012.11.086 10.3390/jcm4091668 10.2147/OTT.S131597 10.1007/s00432-016-2256-7 10.1186/s12935-019-0959-y 10.1016/j.cell.2012.10.002 10.1016/j.cell.2018.05.022 10.1186/s12943-020-01253-y 10.1159/000489208 10.2147/OTT.S207938 10.1097/CMR.0000000000000524 10.1016/j.lfs.2020.117323 10.1016/j.bbrc.2018.05.114 10.1016/j.biopha.2018.08.152 10.1186/s12957-020-01832-9 10.1038/s41419-020-2444-x 10.1186/s12943-020-01191-9 10.1177/0960327120950014 10.1007/s11010-020-03875-8 10.1007/s12013-019-00895-0 10.1038/s41419-020-02799-x 10.1016/j.canlet.2019.05.036 10.1101/gad.270421.115 10.1186/s13059-021-02263-9 10.1038/cr.2015.82 10.1371/journal.pone.0148407 10.1038/jid.2010.222 10.3390/ijms21061930
Oncogene Mecozzi N, Vera O et. al.

Aug 1st, 2021 - Non-coding RNAs are emerging as critical molecules in the genesis, progression, and therapy resistance of cutaneous melanoma. This includes circular RNAs (circRNAs), a class of non-coding RNAs with distinct characteristics that forms through non-c...

Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cuta...
https://doi.org/10.1111/dth.15067
Dermatologic Therapy; Li J, Wang J et. al.

Jul 25th, 2021 - The clinical efficacy of PD-1 inhibitors as an adjuvant treatment for Asian melanoma patients has not yet been determined. This retrospective study analyzed the clinical data of 90 Chinese patients with completely resected, stage III cutaneous or ...

Influence of IL1B (rs16944) and IL1R2 (rs4141134) polymorphisms on aggressiveness and p...
https://doi.org/10.1097/CMR.0000000000000763
Melanoma Research; Torricelli C, Carron J et. al.

Jul 21st, 2021 - Cutaneous melanoma is the most aggressive skin cancer with high mortality. Proinflammatory cytokines can modulate the proliferation and survival of cutaneous melanoma cells. Higher levels of interleukin-1β (IL1B) were associated with tumor cell pr...

see more →

Guidelines  7 results

Systemic Therapy for Melanoma: ASCO Guideline.
https://doi.org/10.1200/JCO.20.00198
Journal of Clinical Oncology : Official Journal of the Am... Seth R, Messersmith H et. al.

Apr 2nd, 2020 - To provide guidance to clinicians regarding the use of systemic therapy for melanoma. ASCO convened an Expert Panel and conducted a systematic review of the literature. A systematic review, one meta-analysis, and 34 additional randomized trials we...

Guidelines of care for the management of primary cutaneous melanoma.
https://doi.org/10.1016/j.jaad.2018.08.055
Journal of the American Academy of Dermatology; Swetter SM, Tsao H et. al.

Nov 6th, 2018 - The incidence of primary cutaneous melanoma continues to increase each year. Melanoma accounts for the majority of skin cancer-related deaths, but treatment is usually curative following early detection of disease. In this American Academy of Derm...

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immun...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977556
Journal for Immunotherapy of Cancer; Sullivan RJ, Atkins MB et. al.

Jun 1st, 2018 - Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patien...

New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distan...
https://doi.org/10.6004/jnccn.2018.0042
Journal of the National Comprehensive Cancer Network : JN... Barker CA, Salama AK

May 23rd, 2018 - The NCCN Guidelines Panel for Melanoma debuted new guidelines for uveal melanoma at the NCCN 23rd Annual Conference. Although uveal melanoma and cutaneous melanoma share the same name, they do have different characteristics and treatments. The NCC...

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and foll...
https://doi.org/10.1093/annonc/mdv297
Annals of Oncology : Official Journal of the European Soc... Dummer R, Hauschild A et. al.

Sep 1st, 2015 - Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2015|Dummer R,Hauschild A,Lindenblatt N,Pentheroudakis G,Keilholz U,|diagnosis,pathology,therapy,

see more →

Drugs  1 results see all →

Clinicaltrials.gov  48 results

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma
https://clinicaltrials.gov/ct2/show/NCT02535078

Apr 21st, 2020 - This study is a Phase Ib/II, multi-center, open-label study of IMCgp100 as a single agent and in combination with durvalumab (MEDI4736) and/or tremelimumab in metastatic cutaneous melanoma. The purpose of this study is to characterize the safety, ...

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
https://clinicaltrials.gov/ct2/show/NCT00539591

Apr 10th, 2020 - This study is for children with malignant melanoma and high risk features (at high risk of melanoma returning or spreading to other parts of the body) or who have recurrent disease. The study has two treatment groups based on the stage of the dise...

pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
https://clinicaltrials.gov/ct2/show/NCT03655756

Feb 27th, 2020 - Six male and/or female adult patients (greater than or equal to 18 years old), of any ethnicity and race, with unresectable stage III or stage IV cutaneous melanoma with accessible lesions, will be eligible for enrollment and treatment with IFx-Hu...

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
https://clinicaltrials.gov/ct2/show/NCT03276832

Jan 30th, 2020 - PRIMARY OBJECTIVES: I. To gain preliminary data of the anti-tumor activity and safety profile of the combination of imiquimod and pembrolizumab in patients with unresectable cutaneous melanoma. SECONDARY OBJECTIVES: I. To compare and contrast (in ...

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
https://clinicaltrials.gov/ct2/show/NCT02581930

Jan 9th, 2020 - PRIMARY OBJECTIVES: I. Estimate rate of objective response (OR: complete response [CR] + partial response [PR]) to ibrutinib administered as single agent in patients with immune checkpoint inhibitor-refractory, or immune checkpoint inhibitor ineli...

see more →

News  98 results

Recent Trend: Melanoma Mortality Declining Rapidly
https://www.medscape.com/viewarticle/955112

Jul 20th, 2021 - Declining trends in melanoma death rates accelerated from 2014 to 2018 in the United States, even as incidence rates increased for both males and females, according to an annual report by several national organizations. "Death rates for cutaneous ...

UV Exposure Likely Not a Melanoma Risk for People of Color
https://www.medscape.com/viewarticle/943086

Dec 23rd, 2020 - NEW YORK (Reuters Health) - The association between ultraviolet (UV) exposure and melanoma is "weak" for skin of color, according to a new systematic review. "I was not surprised to find little to no evidence supporting the association between UV ...

What Happened to Melanoma Care During COVID-19 Sequestration
https://www.medscape.com/viewarticle/940924

Nov 13th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Initial evidence suggests that the deliberate delays in melanoma care that occurred during the COVID-19 shelter-in-place lockdown last spring had ...

Mohs Surgery May Not Boost Survival Over Standard Excision of Melanomas on Trunk, Extremities
https://www.medscape.com/viewarticle/940003

Oct 30th, 2020 - NEW YORK (Reuters Health) - Compared with wide local excision (WLE), Mohs micrographic surgery (MMS) does not appear to increase overall survival in patients with trunk or extremity melanomas, according to a retrospective study. "In contrast to ou...

Melanoma Patients Still at Higher Risk for New Malignancy After Successful Systemic Immunotherapy
https://www.medscape.com/viewarticle/938007

Sep 25th, 2020 - NEW YORK (Reuters Health) - Patients successfully treated for metastatic melanoma with immune-checkpoint inhibitors remain at increased risk for developing new primary cutaneous melanoma, according to a new study. "The 5-year risk was nearly 5%," ...

see more →